ArticleCell cycle (Georgetown, Tex.)2011
Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model.
Article in Cell cycle (Georgetown, Tex.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant.Signal transduction and targeted therapy · 2023Article
- p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).Frontiers in pharmacology · 2022Review
- SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection.International journal of molecular sciences · 2021Review
- Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity.Frontiers in genetics · 2021Review
- The Codon 72Molecular cancer research : MCR · 2019Article
- Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model.Oncogene · 2019Article
- Article
- Article
- The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis.Frontiers in endocrinology · 2018Review
- The p53 R72P polymorphism does not affect the physiological response to ionizing radiation in a mouse model.Cell cycle (Georgetown, Tex.) · 2017Article
- Does p53 codon 72 polymorphism have a prognostic value in carcinoma of the vulva and vagina?Medical oncology (Northwood, London, England) · 2017Article
- A functionally significant SNP in TP53 and breast cancer risk in African-American women.NPJ breast cancer · 2017Article
- The role of the p53 tumor suppressor in metabolism and diabetes.The Journal of endocrinology · 2016Review
- The African-specific S47 polymorphism of p53 alters chemosensitivity.Cell cycle (Georgetown, Tex.) · 2016Article
- Genetic Modifiers of the p53 Pathway.Cold Spring Harbor perspectives in medicine · 2016Review
- Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes.Molecular cancer research : MCR · 2015Article
- Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
- TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Currently there are several dozen human polymorphisms that have been loosely associated with cancer risk. Correlating such variants with cancer risk has been challenging, primarily due to factors such as genetic heterogeneity, contributions of diet and environmental factors, and the difficulty in obtaining large sample sizes for analysis. Such difficulties can be circumvented with the establishment of mouse models for human variants. Recently, several groups have modeled human cancer susceptibility polymorphisms in the mouse. Remarkably, in each case these mouse models have accurately reflected human phenotypes, and clarified the contribution of these variants to cancer risk. We recently reported on a mouse model for the codon 72 polymorphism in p53, and found that this polymorphism regulates the ability to cooperate with NF-kB and induce apoptosis. Here-in we present evidence that this polymorphism impacts the apoptotic function of p53 in a tissue-specific manner; such tissue-specific effects of polymorphic variants represent an added challenge to human cancer risk association studies. The data presented here support the premise that modeling human polymorphisms in the mouse represents a powerful tool to assess the impact of these variants on cancer risk, progression and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.